Alfred Ford, Jr. Sells 13,015 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Alfred Ford, Jr. sold 13,015 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $23.90, for a total value of $311,058.50. Following the completion of the sale, the insider owned 105,839 shares in the company, valued at approximately $2,529,552.10. This represents a 10.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Trading Up 8.1%

KMTS opened at $25.93 on Wednesday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. Kestra Medical Technologies, Ltd. has a one year low of $14.10 and a one year high of $30.00. The company has a market cap of $1.52 billion, a P/E ratio of -10.71 and a beta of 0.58. The business’s 50-day simple moving average is $22.70 and its 200-day simple moving average is $22.51.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The business had revenue of $28.64 million during the quarter. As a group, equities research analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on KMTS. Oppenheimer assumed coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating for the company. The Goldman Sachs Group reduced their target price on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research report on Wednesday, July 15th. Wall Street Zen downgraded Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings cut Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 16th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Kestra Medical Technologies has a consensus rating of “Hold” and an average price target of $27.83.

Key Stories Impacting Kestra Medical Technologies

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Analyst sentiment remains mixed but includes three Buy ratings, with a consensus price target of $27.83. BTIG Research raised its target to $32 and maintained a Buy rating, while Wolfe Research set a $30 objective. Kestra Medical Technologies insider-selling report
• Positive Sentiment: Several institutional investors increased their positions, including Russell Investments Group, Brown Brothers Harriman, Rhumbline Advisers and New Jersey’s Police & Firemen’s Retirement System. These additions provide some support for institutional interest in KMTS.
• Neutral Sentiment: Executives and insiders sold roughly 103,000 shares worth more than $2.2 million between July 30 and August 3. Sellers included CFO Vaseem Mahboob and insiders Brian Daniel Webster, Traci S. Umberger, Alfred J. Ford Jr. and Timothy P. Moran. Because the filings specify tax-related sales, the transactions may reflect equity vesting rather than discretionary selling.
• Negative Sentiment: The number of sellers, including the CFO, could still weigh on investor sentiment and raise concerns about management ownership. Kestra’s latest quarterly loss of $0.67 per share exceeded the expected loss of $0.59, while revenue was $28.64 million and the company remains unprofitable.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Seven Grand Managers LLC purchased a new stake in shares of Kestra Medical Technologies during the fourth quarter worth approximately $2,652,000. Eventide Asset Management LLC grew its position in Kestra Medical Technologies by 5.4% in the 4th quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock valued at $33,671,000 after buying an additional 65,288 shares during the last quarter. Summit Partners Public Asset Management LLC purchased a new position in Kestra Medical Technologies in the 4th quarter valued at $9,282,000. UBS Group AG increased its stake in Kestra Medical Technologies by 34.9% in the 4th quarter. UBS Group AG now owns 270,058 shares of the company’s stock valued at $7,162,000 after buying an additional 69,908 shares during the period. Finally, Jennison Associates LLC raised its position in Kestra Medical Technologies by 15.0% during the 4th quarter. Jennison Associates LLC now owns 219,355 shares of the company’s stock worth $5,817,000 after buying an additional 28,573 shares during the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.